



2026 Bladder & Kidney Cancer Academy Agenda

Westin Denver Airport
8300 Peña Blvd
Denver, CO 80249



Mountain Standard Time Zone		Thursday, September 24, 2026		
Start	End	Title	Speaker	Location
8:00 AM	12:00 PM	Exhibit Hall: Set-Up		Grand Foyer
10:00 AM	6:50 PM	Registration: Attendees & Industry Sponsors		Grand Foyer
12:00 PM	1:00 PM	Attendee Lunch: Product Theater *Closed Session for Merck & Meeting Attendees only		Spruce Ballroom
12:00 PM	1:00 PM	Industry & Exhibitor Lunch		Willow
1:10 PM	1:20 PM	Welcome: 2026 Bladder & Kidney Cancer Academy	Tom Jayram, MD Director, Advanced Therapeutics Center Urology Associates, PC Neal Shore, MD, FACS Director, START Cancer Research Atlantic Urology Specialists	Spruce Ballroom
1:20 PM	1:35 PM	Molecular Imaging in RCC– Where are we today?	Brian Shuch, MD Director UCLA Kidney Cancer Program	Spruce Ballroom
1:35 PM	1:50 PM	Expert Tips & Surgical Pearls for Complex Renal Masses	Brian Shuch, MD Director UCLA Kidney Cancer Program	Spruce Ballroom
1:50 PM	2:05 PM	Radiotherapy in RCC: Localized and Oligometastatic	Tyler P Robin, MD, PhD Associate Professor, Department of Radiation Oncology Director of Genitourinary Radiation Oncology University of Colorado School of Medicine	Spruce Ballroom
2:05 PM	2:50 PM	Cases in Localized RCC	Michael Large, MD (Moderator) Director of Urologic Oncology Community MD Anderson Indianapolis, IN Urology of Indiana Tyler P Robin, MD, PhD Associate Professor, Department of Radiation Oncology Director of Genitourinary Radiation Oncology University of Colorado School of Medicine Brian Shuch, MD Director UCLA Kidney Cancer Program Michael B. Williams, MD, MS Associate Professor Department of Urology Eastern Virginia Medical School Norfolk	Spruce Ballroom
2:50 PM	3:20 PM	Networking Break in Exhibit Area		Grand Foyer
3:20 PM	3:35 PM	Biomarkers in RCC: Are We Ready for Prime Time?	Sumanta K. Pal (Monty) MD, FASCO Professor & Vice Chair of Academic Affairs Department of Medical Oncology	Spruce Ballroom
3:35 PM	3:50 PM	Three Clinical Trials I'm Excited About in Kidney Cancer	Brian Shuch, MD Director UCLA Kidney Cancer Program	Spruce Ballroom
3:50 PM	4:05 PM	Adjuvant therapy in RCC – 0, 1 or 2 agents?	Sumanta K. Pal (Monty) MD, FASCO Professor & Vice Chair of Academic Affairs Department of Medical Oncology	Spruce Ballroom
4:05 PM	4:25 PM	Metastatic RCC for the Urologist: What to Know About the Current Treatment Arsenal	Sumanta K. Pal (Monty) MD, FASCO Professor & Vice Chair of Academic Affairs Department of Medical Oncology	Spruce Ballroom

4:25 PM	5:15 PM	Cases in Advanced RCC	Michael Large, MD (Moderator) Director of Urologic Oncology Community MD Anderson Indianapolis, IN Urology of Indiana	Spruce Ballroom
			Sumanta K. Pal (Monty) MD, FASCO Professor & Vice Chair of Academic Affairs Department of Medical Oncology	
			Tyler P Robin, MD, PhD Associate Professor, Department of Radiation Oncology Director of Genitourinary Radiation Oncology University of Colorado School of Medicine	
			Brian Shuch, MD Director UCLA Kidney Cancer Program	
5:15 PM	5:25 PM	Industry Updates		Spruce Ballroom
5:40 PM	7:00 PM	Welcome Reception		Grand Foyer

Mountain Standard Time Zone		Friday, September 25, 2026		
Start	End	Title	Speaker	Location
7:00 AM	8:00 AM	Attendee Breakfast: Product Theater *Closed Session for Ferring & Meeting Attendees only		Maple
7:00 AM	8:00 AM	Industry & Exhibitor Breakfast		Willow
8:10 AM	8:30 AM	Welcome Back	Tom Jayram, MD Director, Advanced Therapeutics Center Urology Associates, PC Neal Shore, MD, FACS Director, START Cancer Research Atlantic Urology Specialists	Spruce Ballroom
8:30 AM	9:30 AM	IR-NMIBC in Focus: CME Session (1-Hour)		Spruce Ballroom
8:30 AM	8:50 AM	Risk stratification in IR-NMIBC	Bogdana Schmidt MD, MPH, FACS University of Utah (Huntsman Cancer Institute)	Spruce Ballroom
8:50 AM	9:10 AM	Treatment options in IR-NMIBC	Mark Tyson MD MPH Professor of Urology Director, Mayo Clinic in Arizona Cancer Clinical Trial Office Vice Chair, Surgical and Procedural Committee	Spruce Ballroom
9:10 AM	9:30 AM	Emerging options and trials in IR-NMIBC	Sia Daneshmand, MD Professor of Urology & Medicine (Oncology); Director, Urologic Oncology & Clinical Research; Urologic Oncology Fellowship Director; USC Norris Comprehensive Cancer Center	Spruce Ballroom
9:30 AM	10:00 AM	Networking Break in Exhibit Area		Grand Foyer
10:00 AM	10:30 AM	Debate: Durva+ BCG is a preferred approach for HR-NMIBC	Sia Daneshmand, MD (Pro) Professor of Urology & Medicine (Oncology); Director, Urologic Oncology & Clinical Research; Urologic Oncology Fellowship Director; USC Norris Comprehensive Cancer Center Bogdana Schmidt MD, MPH, FACS (Con) University of Utah (Huntsman Cancer Institute)	Spruce Ballroom
10:30 AM	10:45 AM	3 Clinical Trials I'm keeping my eye on in NMIBC	Mark Tyson MD MPH Professor of Urology Director, Mayo Clinic in Arizona Cancer Clinical Trial Office Vice Chair, Surgical and Procedural Committee	Spruce Ballroom
10:45 AM	11:05 AM	Sifting Through the Armamentarium: Which Therapy for Which BCG-Unresponsive Patient?	Sia Daneshmand, MD Professor of Urology & Medicine (Oncology); Director, Urologic Oncology & Clinical Research; Urologic Oncology Fellowship Director; USC Norris Comprehensive Cancer Center	Spruce Ballroom

11:05 AM	11:35 AM	Cases / Panel Discussion - NMIBC	Sia Daneshmand, MD Professor of Urology & Medicine (Oncology); Director, Urologic Oncology & Clinical Research; Urologic Oncology Fellowship Director; USC Norris Comprehensive Cancer Center	Spruce Ballroom
			Suzanne B. Merrill, MD (Moderator) Urologic Oncologist, Bladder Cancer and Advanced Therapeutic Regional Lead for Colorado Urology	
			Bogdana Schmidt MD, MPH, FACS University of Utah (Huntsman Cancer Institute)	
			Mark Tyson MD MPH Professor of Urology Director, Mayo Clinic in Arizona Cancer Clinical Trial Office Vice Chair, Surgical and Procedural Committee	
11:35 AM	11:50 AM	Industry Updates		Spruce Ballroom
12:05 PM	1:05 PM	Attendee Lunch: Product Theater *Closed Session for Immunity Bio & Meeting Attendees only		Maple
12:05 PM	1:05 PM	Industry & Exhibitor Lunch		Willow
1:15 PM	1:40 PM	Beyond Radical Cystectomy: Navigating Contemporary Treatment Options in MIBC	Bogdana Schmidt MD, MPH, FACS University of Utah (Huntsman Cancer Institute)	Spruce Ballroom
1:40 PM	2:05 PM	The New Perioperative Era of Systemic Therapy in MIBC	Jacqueline T. Brown, MD Associate Professor Winship Cancer Institute of Emory University	Spruce Ballroom
2:05 PM	2:20 PM	The Shift Toward Sparing: Evaluating Modern Outcomes in Trimodality MIBC Protocols	Tyler P Robin, MD, PhD Associate Professor, Department of Radiation Oncology Director of Genitourinary Radiation Oncology University of Colorado School of Medicine	Spruce Ballroom
2:20 PM	2:40 PM	Panel: MIBC	Jacqueline T. Brown, MD Associate Professor Winship Cancer Institute of Emory University	Spruce Ballroom
			Sia Daneshmand, MD Professor of Urology & Medicine (Oncology); Director, Urologic Oncology & Clinical Research; Urologic Oncology Fellowship Director; USC Norris Comprehensive Cancer Center	
			Bogdana Schmidt MD, MPH, FACS University of Utah (Huntsman Cancer Institute)	
			Michael B. Williams, MD, MS (Moderator) Associate Professor Department of Urology Eastern Virginia Medical School Norfolk	
2:40 PM	2:55 PM	Industry Updates		Spruce Ballroom
2:55 PM	3:25 PM	Networking Break in Exhibit Area		Grand Foyer
3:25 PM	4:55 PM	The Changing Landscape of I/O Therapy in Urology Practices: CME Session (1.5-Hours)		Spruce Ballroom
3:25 PM	3:55 PM	Indications and Approvals of IO in Urologic Disease settings	Gordon Brown, DO, FACOS Director, Center for Advanced Therapeutics New Jersey Urology	Spruce Ballroom
3:55 PM	4:25 PM	Management of ir-AEs	Jacqueline T. Brown, MD Associate Professor Winship Cancer Institute of Emory University	Spruce Ballroom
4:25 PM	4:55 PM	Operationalizing Checkpoint Inhibitors In Urologic Practice	Tom Jayram, MD Director, Advanced Therapeutics Center Urology Associates, PC	Spruce Ballroom
4:55 PM	6:00 PM	Networking Reception		Grand Foyer
6:00 PM	8:00 PM	Exhibit Hall: Teardown		Grand Foyer